JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

35.9 -4.42

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.76

Max

37.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+33.68% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.6B 5.8B
Vorheriger Eröffnungskurs	40.32
Vorheriger Schlusskurs	35.9

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Jan. 2026, 20:14 UTC

Akquisitionen, Fusionen, Übernahmen

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30. Jan. 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30. Jan. 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30. Jan. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30. Jan. 2026, 22:20 UTC

Ergebnisse

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30. Jan. 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

30. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. Jan. 2026, 21:42 UTC

Ergebnisse

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. Jan. 2026, 21:36 UTC

Ergebnisse

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30. Jan. 2026, 21:33 UTC

Ergebnisse

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30. Jan. 2026, 20:42 UTC

Ergebnisse

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. Jan. 2026, 20:37 UTC

Akquisitionen, Fusionen, Übernahmen

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30. Jan. 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30. Jan. 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30. Jan. 2026, 19:52 UTC

Ergebnisse

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30. Jan. 2026, 19:29 UTC

Market Talk

Ergebnisse

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30. Jan. 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Jan. 2026, 19:09 UTC

Market Talk

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30. Jan. 2026, 19:07 UTC

Market Talk

Canada Performing Well Below Economic Potential -- Market Talk

30. Jan. 2026, 18:46 UTC

Ergebnisse

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30. Jan. 2026, 18:34 UTC

Ergebnisse

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

33.68% Vorteil

12-Monats-Prognose

Durchschnitt 50.33 USD 33.68%

Hoch 67 USD

Tief 34 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.